A Phase 2 interventional study of Sodium nitrite and Saline in Subarachnoid Hemorrhage, sponsored by Hope Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-05-21.
Sponsored by Hope Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 149 studies in Subarachnoid Hemorrhage with a site in United States — 31 open to participants now, 37 under way, 2 of them phase 3. Subarachnoid Hemorrhage · United States.
Among the 149 studies in Subarachnoid Hemorrhage with a site in United States, this one is the 70th largest by enrollment of the 107 interventional ones that give a count, is one of 7 that started in 2010, is one of 18 in phase 2, and was the 26th registered.
511 studies on the registry are indexed under Subarachnoid Hemorrhage; 128 are open to participants now.
Browse Subarachnoid Hemorrhage studies →31 of the 149 studies in Subarachnoid Hemorrhage with a site in United States are open now. Recruiting first, the newest first:
Columbia University · Sites in United States, Brazil, Canada and 2 more countries
Ages 18+
Daniel Raper, MBBS · Sites in United States
Ages 18+
University of Louisville · Sites in United States
Ages 18+
University of Florida · Sites in United States
Ages 18–89
Marshall Holland · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 89 Subarachnoid Hemorrhage studies recruiting now, 56 (63%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
149 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 33 · Phase 3 11 · Phase 4 17
First in 1999; this study’s year is marked. 7 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 57 across 264 interventional studies indexed under Subarachnoid Hemorrhage.
Median enrollment 30 across the 107 interventional studies, 60 across the 42 observational. Of the 94 that completed or were terminated, 38 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 149 have an industry lead sponsor. The 10 most frequent:
Hope Pharmaceuticals is the lead sponsor of 5 studies on the registry; none are open to participants now.
Hope Pharmaceuticals has 2 studies filed under Subarachnoid Hemorrhage — fewer than ten, so there is no comparison to draw.
13 of the studies in Subarachnoid Hemorrhage with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06621329Phase 3University of California, DavisTransnasal Sphenopalatine Ganglion Block for Treatment of Acute Subarachnoid Hemorrhage Associated Headache | 2027-07 |
| NCT07116408Wright State UniversityIntranasal Sphenopalatine Ganglion Blockade for Headaches Following Aneurysmal Subarachnoid Hemorrhage | 2026-11 |
| NCT06103201University of Maryland, BaltimoreHyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury | 2026-11-26 |
| NCT05230134Stanford UniversityCervical Sympathetic Block in Patients With Cerebral Vasospasm | 2026-12 |
| NCT06119061Aaron CookTelavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage | 2026-12 |
Add all 13 to your calendar (.ics) → With an account.
Among the 149 studies in Subarachnoid Hemorrhage with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to examine the safety of a 14 day infusion of sodium nitrite, and to study the pharmacokinetics of nitrite, during a 14 day infusion in patients with ruptured cerebral aneurysms.
Intravenous sodium nitrite has been shown to prevent and to reverse cerebral vasospasm in a primate model of subarachnoid hemorrhage (SAH). This was a Phase IIA dose escalation study of sodium nitrite to determine its safety in patients with aneurysmal SAH and to establish its pharmacokinetics during a 14 day infusion.
Sodium nitrite was delivered intravenously for 14 days in 18 patients with SAH from a ruptured cerebral aneurysm using a dose escalation scheme in three cohorts of 6 patients each (3 nitrite, 3 saline), with a maximum dose of 64 nmol/min/kg. Sodium nitrite blood levels were frequently sampled and measured using mass spectroscopy and blood methemoglobin levels were continuously monitored using a pulse oximeter.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Continuous intravenous infusion of Sodium Nitrite
Drug: Sodium nitrite
Continuous intravenous infusion of saline
Drug: Saline
14 day continuous infusion of one of 3 escalating doses of sodium nitrite: 32 nmol/min/kg, 48 nmol/min/kg, or 64 nmol/min/kg
Also known as: Sodium Nitrite Injection NDC 60267-311-10
14 day continuous infusion of a vehicle control infusion
Also known as: Sterile saline
Mean Plasma Nitrite Concentration (Micromol/L)
Samples for pharmacokinetic analysis were collected from subjects treated with sodium nitrite at -15, -5, 0, 10, 30, 60, and 90 minutes after starting nitrite infusion and then at 2, 4, 6, 8, 12, 24, and every 24 hours after starting nitrite infusion. The sample at the time of starting the infusion was considered to be the time 0 sample. On study day 14 additional blood samples were collected at 0, 10, 30, 60, and 90 minutes and at 2, 4, 6, 8, and 12 hours after stopping nitrite infusion. Blood samples were analyzed for nitrite levels using mass spectroscopy.
Time frame: multiple time points up to the end of day 14
Safety of a 14 Day Infusion of Sodium Nitrite
Development of methemoglobin \> 5% or hypotension (systolic arterial blood pressure \< 90 mm Hg for more than 15 minutes or \< 80 mm Hg) during infusion of sodium nitrite
Time frame: 14 days
Efficacy of 14 Day Infusion of Sodium Nitrite
Development of vasospasm as documented by onset of neurologic symptoms and documentation of narrowing of vessel(s) on cerebral angiogram. Potential clinical vasospasm was evaluated as appropriate, based on the development of focal neurological deficits that suggested cerebral ischemia (such as hemiparesis and speech deficit) or global neurological deficit (altered level of consciousness) that could not be attributed to other etiologies (such as metabolic abnormalities, intracerebral hemorrhage, and hydrocephalus).
Time frame: 14 days
Patients admitted to University of Virginia Medical Center for the treatment of subarachnoid hemorrhage were screened for possible recruitment into this study.
| Milestone | Vehicle Control | Nitrite 32 Nmol/Min/kg | Nitrite 48 Nmol/Min/kg | Nitrite 64 Nmol/Min/kg |
|---|---|---|---|---|
| Started | 9 | 4 | 3 | 3 |
| Completed | 9 | 3 | 3 | 3 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
Samples for pharmacokinetic analysis were collected from subjects treated with sodium nitrite at -15, -5, 0, 10, 30, 60, and 90 minutes after starting nitrite infusion and then at 2, 4, 6, 8, 12, 24, and every 24 hours after starting nitrite infusion. The sample at the time of starting the infusion was considered to be the time 0 sample. On study day 14 additional blood samples were collected at 0, 10, 30, 60, and 90 minutes and at 2, 4, 6, 8, and 12 hours after stopping nitrite infusion. Blood samples were analyzed for nitrite levels using mass spectroscopy.
| micromol/L | 64 Nmol/Min/kg | 48 Nmol/Min/kg | 32 Nmol/Min/kg |
|---|---|---|---|
| Mean Plasma Nitrite Concentration (Micromol/L) | 4.2 ± 0.3 | 4.3 ± 0.4 | 2.6 ± 0.3 |
Development of methemoglobin \> 5% or hypotension (systolic arterial blood pressure \< 90 mm Hg for more than 15 minutes or \< 80 mm Hg) during infusion of sodium nitrite
| Participants | 64 Nmol/Min/kg | 48 Nmol/Min/kg | 32 Nmol/Min/kg | Placebo |
|---|---|---|---|---|
| Safety of a 14 Day Infusion of Sodium Nitrite | 0 | 0 | 0 | 0 |
Development of vasospasm as documented by onset of neurologic symptoms and documentation of narrowing of vessel(s) on cerebral angiogram. Potential clinical vasospasm was evaluated as appropriate, based on the development of focal neurological deficits that suggested cerebral ischemia (such as hemiparesis and speech deficit) or global neurological deficit (altered level of consciousness) that could not be attributed to other etiologies (such as metabolic abnormalities, intracerebral hemorrhage, and hydrocephalus).
| Participants | 64 Nmol/Min/kg | 48 Nmol/Min/kg | 32 Nmol/Min/kg | Placebo |
|---|---|---|---|---|
| Efficacy of 14 Day Infusion of Sodium Nitrite | 1 | 1 | 0 | 3 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nitrite | — | 0/9 (0%) | 0/9 (0%) |
| Vehicle Control | — | 2/9 (22.2%) | 0/9 (0%) |
| Event | Nitrite | Vehicle Control |
|---|---|---|
| AbscessInfections and infestations | 0/9 | 1/9 |
| DeathNervous system disorders | 0/9 | 1/9 |
| Age, Categorical(Participants) | 32 Nmol/Min/kg | Vehicle Control | 48 Nmol/Min/kg | 64 Nmol/Min/kg | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 8 | 3 | 3 | 18 |
| >=65 years | 0 | 1 | 0 | 0 | 1 |
| Age, Continuous(years) | 32 Nmol/Min/kg | Vehicle Control | 48 Nmol/Min/kg | 64 Nmol/Min/kg | Total |
|---|---|---|---|---|---|
| Mean | 50 ± 10 | 52 ± 18.3 | 50 ± 5 | 58 ± 7 | 51 ± 9.9 |
| Sex: Female, Male(Participants) | 32 Nmol/Min/kg | Vehicle Control | 48 Nmol/Min/kg | 64 Nmol/Min/kg | Total |
|---|---|---|---|---|---|
| Female | 3 | 6 | 2 | 2 | 13 |
| Male | 1 | 3 | 1 | 1 | 6 |
| Region of Enrollment(participants) | 32 Nmol/Min/kg | Vehicle Control | 48 Nmol/Min/kg | 64 Nmol/Min/kg | Total |
|---|---|---|---|---|---|
| United States | 4 | 9 | 3 | 3 | 19 |
The record gives a start of Apr 2010, a primary completion of Nov 2010 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2013, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sodium Nitrite
Hope Pharmaceuticals